Q3 Earnings Estimate for Nkarta Issued By HC Wainwright

Nkarta, Inc. (NASDAQ:NKTX – Free Report) – Stock analysts at HC Wainwright issued their Q3 2026 earnings estimates for shares of Nkarta in a research report issued to clients and investors on Monday, November 2nd. HC Wainwright analyst D. Tsao forecasts that the company will earn ($0.46) per share for the quarter. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Nkarta’s current full-year earnings is ($1.60) per share. HC Wainwright also issued estimates for Nkarta’s Q4 2026 earnings at ($0.48) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($2.26) EPS, FY2028 earnings at ($1.76) EPS, FY2029 earnings at ($1.57) EPS and FY2030 earnings at ($1.36) EPS.

Nkarta (NASDAQ:NKTX – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.05).

Several other equities research analysts have also recently commented on NKTX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nkarta in a report on Monday, September 21st. Wall Street Zen lowered Nkarta from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Finally, Stifel Nicolaus lowered their price objective on Nkarta from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Nkarta currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.20.

View Our Latest Research Report on Nkarta

Nkarta Price Performance

Shares of Nkarta stock opened at $1.57 on Wednesday. The stock has a market cap of $112.44 million, a P/E ratio of -1.00 and a beta of 1.24. The stock’s 50 day simple moving average is $2.36 and its 200-day simple moving average is $2.52. Nkarta has a 1-year low of $1.48 and a 1-year high of $3.72.

Hedge Funds Weigh In On Nkarta

Several large investors have recently modified their holdings of NKTX. Abel Hall LLC raised its stake in shares of Nkarta by 65.4% in the 1st quarter. Abel Hall LLC now owns 24,113 shares of the company’s stock valued at $51,000 after acquiring an additional 9,535 shares during the period. Susquehanna Fundamental Investments LLC acquired a new position in shares of Nkarta in the second quarter worth $30,000. Pallas Capital Advisors LLC acquired a new position in shares of Nkarta in the second quarter worth $31,000. Spark Investment Management LLC purchased a new stake in shares of Nkarta during the second quarter worth $33,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Nkarta in the first quarter valued at $30,000. Institutional investors and hedge funds own 80.54% of the company’s stock.

Nkarta News Roundup

Here are the key news stories impacting Nkarta this week:

  • Positive Sentiment: HC Wainwright’s research coverage carried a Buy rating, signaling a favorable view despite continued expected losses. HC Wainwright Begins Coverage on Nkarta
  • Neutral Sentiment: Nkarta released its third-quarter 2026 financial results and a business update; no further business-update details were provided in the article excerpt. Nkarta Q3 2026 Results and Business Update
  • Negative Sentiment: Nkarta reported a third-quarter loss of $0.45 per share, wider than analysts’ expected loss of $0.40. The earnings miss is a likely source of selling pressure. HC Wainwright’s estimates also point to continued losses in coming years, including a projected $2.26-per-share loss for 2027.

Nkarta Company Profile

(Get Free Report)

Nkarta, Inc is a clinical-stage biotechnology company focused on developing engineered natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s platform is designed to produce allogeneic, or donor-derived, NK cells that can be engineered with chimeric antigen receptors (CARs) to recognize and attack targeted cells.

Nkarta’s research and development programs have included NKX019, a CD19-targeted CAR NK-cell therapy investigated for B-cell malignancies and autoimmune disorders, and NKX101, an NKG2D-targeted CAR NK-cell therapy developed for certain solid tumors.

Recommended Stories

Earnings History and Estimates for Nkarta (NASDAQ:NKTX)

Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.